Advancing human longevity and therapeutic efficacy through precision medicine, genomic engineering, and AI-driven clinical research.
Zenth Health Sciences operates as a fully integrated life sciences vertical, leveraging cross-divisional synergies in AI, robotics, and logistics to accelerate therapeutic discovery and global distribution.
Our division spans the entire value chain from target identification and clinical validation to manufacturing, regulatory approval, and post-market surveillance. By integrating Zenth Digital Systems' AI modeling and Aevum Robotics' automated lab infrastructure, we've reduced early-stage R&D timelines by 42%.
Committed to ethical innovation and equitable access, Zenth Health Sciences maintains ISO 13485, FDA cGMP, and EMA GMP certifications across all manufacturing and clinical sites. Our decentralized clinical trial networks span 62 countries, ensuring diverse population representation and real-world data integrity.
View R&D Pipeline →Small molecule and biologic drug discovery focusing on oncology, immunology, and metabolic disorders.
CRISPR-based editing, CAR-T engineering, and viral vector platforms for hereditary and acquired diseases.
Implantable devices, surgical robotics, diagnostic imaging, and AI-assisted operating theater systems.
Remote patient monitoring, EHR interoperability platforms, and AI triage networks serving 140M+ patients.
Multi-omics profiling, liquid biopsy assays, and predictive biomarker discovery for personalized treatment.
Current therapeutic candidates advancing through preclinical and clinical validation stages.
| Candidate | Target | h>MechanismPhase | Indication | |
|---|---|---|---|---|
| ZHS-492 | PD-1 / CD47 | Bispecific mAb | Phase III | Advanced Melanoma |
| ZHS-881 | SOD1 / MAPT | AAV9 Gene Silencing | Phase II | ALS / Tauopathy |
| ZHS-204 | GLP-1 / GIP | Dual Agonist Peptide | Phase III | Type 2 Diabetes / Obesity |
| ZHS-773 | EGFR Exon20ins | Irreversible Inhibitor | Phase II | NSCLC |
| ZHS-115 | IL-17A / IL-17F | Fc-optimized Antibody | Phase I | Psoriasis / IBD |
| ZHS-990 | PCSK9 | mRNA Lipid Nanoparticle | Preclinical | Familial Hypercholesterolemia |
Former VP of Clinical Development at Novartis. 22 years in biopharma leadership. MD/PhD Johns Hopkins.
Pioneer in CRISPR delivery systems. Former Director at Kyoto University Institute. 140+ peer-reviewed publications.
Ex-FDA Associate Commissioner. Expert in global clinical trial design and post-market pharmacovigilance.
Full adherence to cGMP, GLP, and GCP standards
End-to-end encryption for patient and trial data
Independent ethics review for all human subjects research
Aligned with global health equity and access initiatives
Explore clinical trial participation, strategic licensing, supply chain partnerships, or investment opportunities across our biomedical portfolio.